BioSkryb

BioSkryb Genomics, established in 2018, is a life sciences company focused on single-cell molecular analysis. The company was co-founded by Jay West, PhD, and Charles Gawad, MD/PhD. Their core technology, Primary Template-directed Amplification (PTA), was developed at St. Jude Children's Research Hospital and licensed to the company. Dr. Gawad, a physician-scientist at Stanford University, invented the PTA technology while at St. Jude, driven by his research at the intersection of biotechnology, computational biology, and clinical medicine to understand genetic variation in single cells, particularly in cancer evolution and antibiotic resistance. Dr. West, an experienced entrepreneur in molecular biology and diagnostics technologies, serves as the company's Chief Technology Officer after initially being the CEO.

The company is headquartered in Durham, North Carolina, and operates in the genomics and molecular diagnostics market. Its business model centers on selling kits, providing services, and offering a bioinformatics platform to researchers and clinicians in fields like oncology, microbiology, and genetics. BioSkryb generates revenue through the sale of its product lines and service fees for genomic analysis and custom assays. Key clients include academic research institutions, pharmaceutical companies, and clinical diagnostics labs working with scarce genetic material.

BioSkryb's product portfolio is built around its proprietary PTA technology, which enables more uniform and accurate whole genome and whole transcriptome amplification from a single cell than previous methods. The flagship product lines, ResolveDNA® and ResolveOME™, provide the tools for this analysis. ResolveDNA® focuses on whole genome amplification, allowing for high-resolution detection of genomic variations like SNVs and CNVs from a single cell with approximately 97% genomic coverage. ResolveOME™ is a multi-omic solution that simultaneously captures both the whole genome and the full-length transcriptome from the same cell, eliminating the need to split samples. This provides a unified view of how genomic variations impact gene expression. The products are sold as end-to-end kits that include amplification and library preparation reagents, with a workflow that can be completed in under eight hours. Complementing these kits is the BaseJumper® cloud-based bioinformatics platform, which provides automated data processing and visualization tools for analysis.

Since its inception, BioSkryb has secured significant funding to fuel its growth and commercialization efforts. A seed round in January 2020, led by Anzu Partners with participation from Wilson Sonsini Goodrich & Rosati, raised $11.5 million. By May 2025, the company's total funding reached $31.5 million, including a $20 million Later Stage VC deal. The company has also pursued strategic partnerships to expand its reach, including collaborations with Research Instruments for distribution in Southeast Asia and with Tecan Group and Ultima Genomics to develop high-throughput workflows and advance oncology research. Keywords: single-cell genomics, multi-omics, primary template-directed amplification, whole genome amplification, whole transcriptome amplification, genomic analysis, molecular discovery, cancer research, ResolveDNA, ResolveOME, clonal heterogeneity, DNA variant calling, single nucleotide variants, copy number variants, translational research, clinical diagnostics, low-input DNA sequencing, bioinformatics platform, BaseJumper, Jay West, Charles Gawad, Anzu Partners, liquid biopsy, cellular heterogeneity, gene editing analysis, preimplantation genetic testing, microbiology, immunology, neurology